论文部分内容阅读
目的研究手术联合米非司酮治疗子宫内膜异位症(内异症)的临床效果及应用可行性。方法选择本院内异征患者76例,随机分为单纯手术组(对照组)例与手术联合米非司酮治疗组,观察其疗效。结果术后3个月时,米非司酮组痛经、非经期下腹痛、性交痛、子宫直肠窝结节、结节触痛和子宫活动受限的缓解率分别为100%、85.7%、90.0%、85.1%、89.2%和100.0%,对照组分别为64.2%、33.3%、55.6%、33.3%、50.0%和50.0%。2组比较,用药组的征状、体征改善情况明显优于对照组(P<0.05)。结论内异症术后术后加用米非司酮可廷长征状暖解时间,复发率低,妊娠率高,故术后加用米非司酮是治疗内异症的较好途径。
Objective To study the clinical effect and feasibility of operation combined with mifepristone in the treatment of endometriosis (endometriosis). Methods Sixty-six patients with heterotoleic syndrome were selected and randomly divided into simple surgery group (control group) and operation combined with mifepristone treatment group. The curative effect was observed. Results At 3 months after operation, the remission rates of dysmenorrhea, non-menstrual abdominal pain, painful intercourse, uterine rectal fossa, nodular tenderness and uterine motion restriction were 100%, 85.7%, 90.0 %, 85.1%, 89.2% and 100.0% in the control group and 64.2%, 33.3%, 55.6%, 33.3%, 50.0% and 50.0% in the control group respectively. Compared with the control group, the symptoms and signs of the treatment group were significantly better than those of the control group (P <0.05). Conclusion Endometriosis postoperatively with mifepristone can be long-warming symptoms of Cingchi time, low recurrence rate, high pregnancy rate, so the postoperative use of mifepristone is a better way to treat endometriosis.